CORESTEMCHEMON Inc. (KOSDAQ:166480)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,265.00
+70.00 (2.19%)
At close: Apr 28, 2026
-8.29%
Market Cap 144.84B
Revenue (ttm) 20.16B
Net Income (ttm) -26.83B
Shares Out 44.36M
EPS (ttm) -903.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 283,473
Average Volume 489,105
Open 3,200.00
Previous Close 3,195.00
Day's Range 3,165.00 - 3,300.00
52-Week Range 1,014.00 - 4,100.00
Beta 1.27
RSI 66.60
Earnings Date Apr 3, 2026

About CORESTEMCHEMON

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2003
Employees 36
Stock Exchange KOSDAQ
Ticker Symbol 166480
Full Company Profile

Financial Performance

In 2025, CORESTEMCHEMON's revenue was 20.16 billion, a decrease of -29.91% compared to the previous year's 28.76 billion. Losses were -26.83 billion, 2.21% more than in 2024.

Financial Statements

News

There is no news available yet.